Back to News & Events

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Share this

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.